Indication
Hemolytic Anemia
4 clinical trials
2 products
Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Subjects With Pyruvate Kinase Deficiency Who Are Regularly Transfused, Followed by a 5-Year Open-label Extension PeriodStatus: Active (not recruiting), Estimated PCD: 2024-05-01
Product
MitapivatClinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Subjects With Pyruvate Kinase Deficiency Who Are Not Regularly Transfused, Followed by a 5-Year Open-label Extension PeriodStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
Evaluation of the Safety,Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of MitapivatStatus: Active (not recruiting), Estimated PCD: 2028-02-28
Clinical trial
The Safety of Repurposing Daratumumab for Relapsed or Refractory Autoimmune Antibody Mediated Hemolytic AnemiaStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Product
Daratumumab / Hyaluronidase